{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T05:36:24Z","timestamp":1790660184630,"version":"4.1.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,1,14]],"date-time":"2023-01-14T00:00:00Z","timestamp":1673654400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,1,14]],"date-time":"2023-01-14T00:00:00Z","timestamp":1673654400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The death rate from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections in 2022 was lower than the death rate in 2021, when the infection rate increased. Hybrid immunity provided by a combination of vaccination and infection, including asymptomatic infection, may confer effective protection against death. We explored the combined effect of asymptomatic infection and hybrid immunity by studying T-cell and antibody responses against SARS-CoV-2 among individuals treated in home health care services 6\u00a0months after SARS-CoV-2 exposure. Asymptomatic SARS-CoV-2 infection was demonstrated in 24.4% of close contacts. The levels of immunity were not different between patients and close contacts. Anti-RBD IgG against SARS-CoV-2 increased in a dose-dependent manner with the number of vaccine doses. Interestingly, the T-cell response decreased soon after a booster dose of vaccine. Asymptomatic SARS-CoV-2 infection could not enhance immunity against SARS-CoV-2 among vaccinated close contacts. Full vaccination was crucial to provide hybrid immunity. However, when designing vaccine strategies, T-cell exhaustion after multiple vaccinations should be considered.<\/jats:p>","DOI":"10.1038\/s41598-023-28101-5","type":"journal-article","created":{"date-parts":[[2023,1,14]],"date-time":"2023-01-14T06:02:38Z","timestamp":1673676158000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Hybrid and herd immunity 6\u00a0months after SARS-CoV-2 exposure among individuals from a community treatment program"],"prefix":"10.1038","volume":"13","author":[{"given":"Parawee","family":"Chevaisrakul","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Putthapoom","family":"Lumjiaktase","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pongtorn","family":"Kietdumrongwong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ittiporn","family":"Chuatrisorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pongsan","family":"Chatsangjaroen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nittaya","family":"Phanuphak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,1,14]]},"reference":[{"key":"28101_CR1","unstructured":"https:\/\/ourworldindata.org\/explorers\/coronavirus-data-explorer."},{"key":"28101_CR2","unstructured":"https:\/\/ourworldindata.org\/covid-deaths-by-vaccination."},{"key":"28101_CR3","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1056\/NEJMoa2118691","volume":"386","author":"V Hall","year":"2022","unstructured":"Hall, V. et al. Protection against SARS-CoV-2 after Covid-19 vaccination and previous infection. NEJM 386, 1207\u20131220 (2022).","journal-title":"NEJM"},{"key":"28101_CR4","doi-asserted-by":"publisher","first-page":"1724","DOI":"10.1038\/s41467-021-22036-z","volume":"12","author":"Z Wang","year":"2021","unstructured":"Wang, Z. et al. Exposure to SARS-CoV-2 generates T-cell memory in the absence of a detectable viral infection. Nat. Commun. 12, 1724 (2021).","journal-title":"Nat. Commun."},{"key":"28101_CR5","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1038\/s41590-021-00902-8","volume":"22","author":"J Zuo","year":"2021","unstructured":"Zuo, J. et al. Robust SARS-CoV-2-specific T cell immunity is maintained at 6 months following primary infection. Nat. Immunol. 22, 620\u2013626 (2021).","journal-title":"Nat. Immunol."},{"key":"28101_CR6","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1056\/NEJMoa2116414","volume":"386","author":"RL Atmar","year":"2022","unstructured":"Atmar, R. L. et al. Homologous and heterologous Covid-19 booster vaccinations. N. Engl. J. Med. 386, 1046\u20131057 (2022).","journal-title":"N. Engl. J. Med."},{"key":"28101_CR7","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1038\/s41591-022-01704-7","volume":"28","author":"SMS Cheng","year":"2022","unstructured":"Cheng, S. M. S. et al. Neutralizing antibodies against the SARS-CoV-2 Omicron variant BA.1 following homologous and heterologous CoronaVac or BNT162b2 vaccination. Nat. Med. 28, 486\u2013489 (2022).","journal-title":"Nat. Med."},{"key":"28101_CR8","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.4014\/jmb.2111.11026","volume":"31","author":"SS Mattoo","year":"2021","unstructured":"Mattoo, S. S. & Myoung, J. A promising vaccination strategy against COVID-19 on the horizon: Heterologous immunization. J. Microbiol. Biotechnol. 31, 1601\u20131614 (2021).","journal-title":"J. Microbiol. Biotechnol."},{"key":"28101_CR9","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1038\/s41590-021-00949-7","volume":"22","author":"JL Collier","year":"2021","unstructured":"Collier, J. L., Weiss, S. A., Pauken, K. E., Sen, D. R. & Sharpe, A. H. Not-so-opposite ends of the spectrum: CD8+ T cell dysfunction across chronic infection, cancer and autoimmunity. Nat. Immunol. 22, 809\u2013819 (2021).","journal-title":"Nat. Immunol."},{"key":"28101_CR10","doi-asserted-by":"publisher","first-page":"5061","DOI":"10.1038\/s41467-021-25167-5","volume":"12","author":"DT Skelly","year":"2021","unstructured":"Skelly, D. T. et al. Two doses of SARS-CoV-2 vaccination induce robust immune responses to emerging SARS-CoV-2 variants of concern. Nat. Commun. 12, 5061 (2021).","journal-title":"Nat. Commun."},{"key":"28101_CR11","doi-asserted-by":"publisher","first-page":"2670","DOI":"10.1038\/s41467-022-30340-5","volume":"13","author":"F Zuo","year":"2022","unstructured":"Zuo, F. et al. Heterologous immunization with inactivated vaccine followed by mRNA-booster elicits strong immunity against SARS-CoV-2 Omicron variant. Nat. Commun. 13, 2670 (2022).","journal-title":"Nat. Commun."},{"key":"28101_CR12","doi-asserted-by":"publisher","first-page":"4631","DOI":"10.1038\/s41467-022-32324-x","volume":"13","author":"M Reinscheid","year":"2022","unstructured":"Reinscheid, M. et al. COVID-19 mRNA booster vaccine induces transient CD8+ T effector cell responses while conserving the memory pool for subsequent reactivation. Nat. Commun. 13, 4631 (2022).","journal-title":"Nat. Commun."},{"key":"28101_CR13","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1038\/s41590-021-01122-w","volume":"23","author":"P Moss","year":"2022","unstructured":"Moss, P. The T cell immune response against SARS-CoV-2. Nat. Immunol. 23, 186\u2013193 (2022).","journal-title":"Nat. Immunol."},{"key":"28101_CR14","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/S0140-6736(21)02718-5","volume":"399","author":"ASV Stuart","year":"2022","unstructured":"Stuart, A. S. V. et al. Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): A single-blind, randomised, phase 2, non-inferiority trial. Lancet 399, 36\u201349 (2022).","journal-title":"Lancet"},{"key":"28101_CR15","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1038\/s41586-021-04120-y","volume":"600","author":"B Pozzetto","year":"2021","unstructured":"Pozzetto, B. et al. Immunogenicity and efficacy of heterologous ChAdOx1-BNT162b2 vaccination. Nature 600, 701\u2013706 (2021).","journal-title":"Nature"},{"key":"28101_CR16","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.ijid.2021.08.048","volume":"111","author":"CS van Dam","year":"2021","unstructured":"van Dam, C. S. et al. Herpes zoster after COVID vaccination. Int. J. Infect. Dis. 111, 169\u2013171 (2021).","journal-title":"Int. J. Infect. Dis."},{"key":"28101_CR17","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1126\/science.abj2258","volume":"372","author":"S Crotty","year":"2021","unstructured":"Crotty, S. Hybrid immunity, COVID-19 vaccine responses provide insights into how the immune system perceives threats. Science 372, 1392\u20131393 (2021).","journal-title":"Science"},{"key":"28101_CR18","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1126\/sciimmunol.abo1303","volume":"7","author":"S Vardhana","year":"2022","unstructured":"Vardhana, S., Baldo, L., Moriceii, W. G. & Wherry, E. J. Understanding T cell response to COVID-19 is essential for informing public health strategies. Sci. Immunol. 7, 1303 (2022).","journal-title":"Sci. Immunol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-28101-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-28101-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-28101-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,14]],"date-time":"2023-01-14T06:05:14Z","timestamp":1673676314000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-28101-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,14]]},"references-count":18,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["28101"],"URL":"https:\/\/doi.org\/10.1038\/s41598-023-28101-5","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-1857122\/v1","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,14]]},"assertion":[{"value":"14 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 January 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 January 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"PK is employed by the funder of this research as Director of Research and holds shares in BDMS for personal purchasing. PAC, PL, IC, POC and NP have no competing interests to declare.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"763"}}